GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

01

A Second Lu-177 DOTATATE (Bexlutry) Arrives for GEP-NETs: US FDA | September 2026

What’s New? The FDA has approved Bexlutry (lutetium Lu-177 dotatate) for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut NETs. Bexlutry becomes a...

02

ASTRO 2026 Expands the Role of Radiation Therapy in Pancreatic Cancer: ASTRO | September 2026

Introduction: The role of radiation therapy (RT) in pancreatic cancer has remained controversial, particularly as systemic therapy has improved. The updated ASTRO guideline incorporates newer trials and advances...

03

Neutropenic Diet Offers Little Advantage Over a Liberalised Diet in Cancer: JCO Oncology Practice | 2026

Introduction: The neutropenic diet traditionally restricts fresh fruits, vegetables, and other foods considered potential sources of infection in immunocompromised patients. Despite widespread historical use, whether these restrictions actually...

04

Can Dual-Targeted CAR-T Break the Solid-Tumor Barrier in Colorectal Cancer?: FDA News | September 2026

What’s New? The FDA has cleared a first-in-human trial of an experimental dual-targeted CAR T-cell therapy developed for advanced colorectal cancer, with clinical testing expected to begin in...

05

MATTERHORN: Durvalumab + FLOT Delivers an Overall Survival Benefit: The Lancet | September 2026

What Did the Study Find? MATTERHORN randomized 948 patients with resectable gastric or gastro-oesophageal junction adenocarcinoma to perioperative durvalumab + FLOT or placebo + FLOT. Durvalumab significantly improved...

06

Early-Onset Gastroesophageal Cancer: ESMO GI Oncology | September 2026

What Did the Study Find? This meta-analysis of 45 studies, including >650,000 patients, compared adenocarcinomas of the distal esophagus, GEJ, and stomach diagnosed before age 50 with later-onset...

07

FDA Withdraws Adagrasib–Cetuximab Indication for KRAS G12C Metastatic CRC: US FDA | September 2026 | Regulatory Update

Introduction: Adagrasib + cetuximab received accelerated FDA approval for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC). Following failure of the confirmatory KRYSTAL-10 Phase III trial to demonstrate...

08

ANCHOR Phase III: Oral Anlotinib Fails to Displace Bevacizumab in First-Line mCRC: Signal Transduction and Targeted Therapy | September 2026

Introduction: Bevacizumab plus chemotherapy remains an established first-line option for metastatic colorectal cancer (mCRC). ANCHOR tested whether the oral multitargeted TKI anlotinib + CapeOX could provide a convenient...

09

NordICC at 13 Years: Colonoscopy Prevents CRC, but Mortality Benefit Remains Uncertain: The Lancet | September 2026

Introduction: Colonoscopy can detect and remove precancerous lesions, but randomised evidence demonstrating its population-level impact remains limited. NordICC provides long-term data on whether invitation to a single screening...

10

Tumor Regression After Neoadjuvant Therapy- Does TRG Really Predict Survival? ESMO GI Oncology | 2026

What Did the Study Find? This 19-year real-world study evaluated 692 patients with locally advanced, resectable gastroesophageal adenocarcinoma, including 394 who received neoadjuvant systemic therapy. Most patients showed...

Previous
1220
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer